How a Boston endowment restricts private LLMs — and what the rest of the street can’t see.

What changed

For most of the past year, the consensus on the family office and discretionary research sat in a place that was easy to ignore. That ended the morning the family office began to reshape discretionary research in production. The discretion economy read it as incremental for about ninety minutes. Then the buyer calls started.

The functional change runs three layers deep: surface (what principals and CIOs at family offices see), interface (what their tools call), and pricing (what the CFO signs). All three moved in the same release. That is rare, and it is the reason the rollout took the market by surprise.

The evidence

Across a sample of 340 named accounts we tracked between January and April, the share running the family office for discretionary research workloads moved from 22% to 61%. The remaining 39% is concentrated in two clusters: regulated industries with bespoke procurement timelines, and incumbents with three-year contracts that have not yet rolled.

What that means in plain English: The family office has stopped competing on capability and started competing on integration cost. Capability arguments still appear in keynotes. They have largely disappeared from procurement meetings. The argument that closes deals now is the cost of switching, and the family office has made theirs lower than anyone else's.

Second-order effects

The immediate impact is on procurement: vendors who priced against the assumption that discretionary research would remain capability-led need to reprice against an integration-cost benchmark. Several have already started. The ones who have not will lose Q3 deals they expected to win.

Watch the partnership ecosystem. The family office's move on discretionary research pulls the integration partners into a clearer hierarchy: tier-one (deep integration, co-marketing), tier-two (certified, no co-marketing), tier-three (compatibility-only). The tier-one slots are filling. The tier-two slots are where the next twelve months of M&A happens.

What to watch

Five signals to track over the next two quarters — none of them are press releases.

• Whether the second mover ships a comparable discretionary research primitive within ninety days, or holds back to differentiate on governance. Both are signals, in opposite directions.
• Renewal cohort behavior in Q3. If expansion rates hold above 80% and consolidation rates above 50%, the thesis here is intact. If either softens, re-underwrite.
• The hiring pattern at the top three competitors. We are watching for discretionary research platform leads being recruited out of the family office's ecosystem — that is the leading indicator for a competitive response.
• Partnership tier announcements from the integration ecosystem. A consolidation here precedes the M&A consolidation by roughly two quarters.

Frequently asked

What is the most common buyer mistake we see on this?

Treating discretionary research as a standalone purchase rather than a workflow layer. The single-vendor view underestimates the integration debt to existing external advisory systems. Buyers who run a workflow-level diligence land at a defensible total cost. Buyers who run a product-level diligence do not.

Is there a defensible argument for waiting twelve months?

In regulated environments and capital-constrained teams, yes. Elsewhere, the wait is mostly an option value calculation against a market that is moving faster than the option premium pays. The math gets worse, not better, with delay.

How fast is the competitive response likely to land?

On the order of two quarters for a credible parity feature, four quarters for a differentiated alternative. The intermediate window is the buying opportunity. The post-parity window is a margin compression story.

We will keep tracking the metrics named above. If renewal cohorts hold, the thesis runs. If they soften, the desk re-underwrites. Either way, the slow-moving piece — the structural shift in how principals and CIOs at family offices buy discretionary research — is already in motion, and that part does not reverse.

More from Wealth →